As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...

Immune checkpoint blockade (ICB) therapies have revolutionized cancer treatment, yet many tumors remain resistant. Now, ...

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

Fact checked by Nick Blackmer Karen Peterson was diagnosed with stage 1 triple-negative breast cancer in 2015. After undergoing three months of chemotherapy with difficult side effects, she made the ...

Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and ...

Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival ...

Panelists discuss how current NCCN guidelines for metastatic anal cancer recommend carboplatin-paclitaxel as preferred first-line therapy, with the recent addition of carboplatin-paclitaxel plus ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

Germany has become one of the world’s leading destinations for advanced cancer care, offering cutting-edge therapies, ...

Lung cancer may be curable, depending on a number of factors, including your age, health, stage of cancer, and how it ...